Access the full text.
Sign up today, get DeepDyve free for 14 days.
T. Meijer, M. Burgmans, E. Leede, L. Geus-Oei, B. Boekestijn, H. Handgraaf, D. Hilling, J. Lutjeboer, J. Vuijk, C. Martini, A. Erkel, R. Meer, F. Tijl, F. Speetjens, E. Kapiteijn, A. Vahrmeijer (2020)
Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II StudyAnnals of Surgical Oncology, 28
T. Meijer, M. Burgmans, M. Fiocco, L. Geus-Oei, E. Kapiteijn, E. Leede, C. Martini, R. Meer, F. Tijl, A.L. Vahrmeijer (2019)
Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems’ Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II TrialCardiovascular and Interventional Radiology, 42
E. Rossi, M. Pagliara, Daniela Orteschi, T. Dosa, M. Sammarco, C. Caputo, G. Petrone, G. Rindi, M. Zollino, M. Blasi, A. Cassano, E. Bria, G. Tortora, G. Schinzari (2019)
Pembrolizumab as first-line treatment for metastatic uveal melanomaCancer Immunology, Immunotherapy, 68
T. Tong, M. Kooij, F. Speetjens, A. Erkel, R. Meer, J. Lutjeboer, E. Meerten, C. Martini, R. Zoethout, F. Tijl, C. Blank, M. Burgmans, E. Kapiteijn (2021)
Combining Hepatic Percutaneous Perfusion With Ipilimumab Plus Nivolumab In Advanced Uveal Melanoma (CHOPIN): Study Protocol For A Phase Ib/Randomized Phase II Trial.
M. Valsecchi (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.The New England journal of medicine, 373 13
J. Pingpank, S. Libutti, R. Chang, Bradford Wood, Z. Neeman, A. Kam, W. Figg, S. Zhai, T. Beresneva, G. Seidel, H. Alexander (2005)
Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 15
T. Tong, M. Kooij, F. Speetjens, A. Erkel, R. Meer, J. Lutjeboer, E. Meerten, C. Martini, R. Zoethout, F. Tijl, C. Blank, M. Burgmans, E. Kapiteijn (2022)
Combining Hepatic Percutaneous Perfusion with Ipilimumab plus Nivolumab in advanced uveal melanoma (CHOPIN): study protocol for a phase Ib/randomized phase II trialTrials, 23
Junko Johansson, Jan Siarov, R. Kiffin, J. Mölne, J. Mattsson, P. Naredi, R. Bagge, A. Martner, P. Lindnér (2020)
Presence of tumor-infiltrating CD8+ T cells and macrophages correlates to longer overall survival in patients undergoing isolated hepatic perfusion for uveal melanoma liver metastasisOncoimmunology, 9
C. Blomen, Julian Kött, Tabea Hartung, Leopold Torster, C. Gebhardt (2021)
Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?Cancers, 13
M. Pelster, S. Gruschkus, R. Bassett, D. Gombos, M. Shephard, L. Posada, Maura Glover, Rinata Simien, A. Diab, P. Hwu, B. Carter, S. Patel (2020)
Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology
EA Rozeman (2020)
252Melanoma Res, 30
J. Piulats, E. Espinosa, L. Merino, M. Varela, L. Carrión, S. Martı́n-Algarra, R. Castro, T. Curiel, D. Rodríguez-Abreu, M. Redrado, M. Gomà, A. Rullán, A. González, A. Berrocal-Jaime (2021)
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).Journal of clinical oncology : official journal of the American Society of Clinical Oncology
A. Rowcroft, B. Loveday, B. Thomson, S. Banting, B. Knowles (2019)
Systematic review of liver directed therapy for uveal melanoma hepatic metastases.HPB : the official journal of the International Hepato Pancreato Biliary Association
L. Seymour, J. Bogaerts, A. Perrone, R. Ford, Lawrence Schwartz, L. Schwartz, S. Mandrekar, N. Lin, S. Litière, J. Dancey, A. Chen, F. Hodi, P. Therasse, O. Hoekstra, L. Shankar, J. Wolchok, M. Ballinger, M. Ballinger, M. Ballinger, C. Caramella, E. Vries (2017)
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.The Lancet. Oncology, 18 3
Junko Johansson, R. Kiffin, A. Andersson, P. Lindnér, P. Naredi, R. Bagge, A. Martner (2018)
Isolated Limb Perfusion With Melphalan Triggers Immune Activation in Melanoma PatientsFrontiers in Oncology, 8
I. Karydis, P. Chan, M. Wheater, E. Arriola, P. Szlosarek, C. Ottensmeier (2016)
Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanomaOncoimmunology, 5
J. Larkin, V. Chiarion-Sileni, R. Gonzalez, J. Grob, P. Rutkowski, C. Lao, C. Cowey, D. Schadendorf, J. Wagstaff, R. Dummer, P. Ferrucci, M. Smylie, D. Hogg, A. Hill, I. Márquez-Rodas, J. Haanen, M. Guidoboni, M. Maio, P. Schöffski, M. Carlino, C. Lebbé, G. McArthur, P. Ascierto, G. Daniels, G. Long, L. Bastholt, J. Rizzo, Á. Balogh, A. Moshyk, F. Hodi, J. Wolchok (2019)
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.The New England journal of medicine
T. Meijer, L. Geus-Oei, C. Martini, Fred Tijl, M. Sitsen, A. Erkel, R. Meer, E. Kapiteijn, A.L. Vahrmeijer, M. Burgmans (2019)
Embolization of variant hepatic arteries in patients undergoing percutaneous hepatic perfusion for unresectable liver metastases of ocular melanoma.Diagnostic and interventional radiology
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
C. Gonsalves, R. Adamo, D. Eschelman (2020)
Locoregional Therapies for the Treatment of Uveal Melanoma Hepatic MetastasesSeminars in Interventional Radiology, 37
E. Leede, M. Burgmans, T. Meijer, C. Martini, F. Tijl, J. Vuyk, A. Erkel, C. Velde, E. Kapiteijn, A.L. Vahrmeijer (2017)
Prospective Clinical and Pharmacological Evaluation of the Delcath System’s Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with MelphalanCardiovascular and Interventional Radiology, 40
A. Algazi, K. Tsai, A. Shoushtari, R. Munhoz, Z. Eroglu, J. Piulats, P. Ott, Douglas Johnson, Jimmy Hwang, A. Daud, J. Sosman, R. Carvajal, B. Chmielowski, M. Postow, J. Weber, R. Sullivan (2016)
Clinical outcomes in metastatic uveal melanoma treated with PD‐1 and PD‐L1 antibodiesCancer, 122
D. Minor, Kevin Kim, R. Tong, Max Wu, M. Kashani-Sabet, M. Orloff, D. Eschelman, C. Gonsalves, R. Adamo, P. Anné, J. Luke, D. Char, Takami Sato (2022)
A Pilot Study of Hepatic Irradiation with Yttrium-90 Microspheres Followed by Immunotherapy with Ipilimumab and Nivolumab for Metastatic Uveal MelanomaCancer Biotherapy & Radiopharmaceuticals, 37
M. Heppt, T. Amaral, K. Kähler, L. Heinzerling, J. Hassel, M. Meissner, N. Kreuzberg, C. Loquai, L. Reinhardt, J. Utikal, E. Dabrowski, A. Gesierich, C. Pföhler, P. Terheyden, K. Thoms, L. Zimmer, T. Eigentler, M. Kirchberger, H. Stege, F. Meier, M. Schlaak, C. Berking (2019)
Combined immune checkpoint blockade for metastatic uveal melanoma: a retrospective, multi-center studyJournal for Immunotherapy of Cancer, 7
M. Kooij, A. Joosse, F. Speetjens, G. Hospers, C. Bisschop, J. Groot, R. Koornstra, C. Blank, E. Kapiteijn (2017)
Anti-PD1 treatment in metastatic uveal melanoma in the NetherlandsActa Oncologica, 56
V. Aedo-Lopez, C. Gerard, S. Boughdad, B. Moura, G. Berthod, A. Digklia, K. Homicsko, N. Schaefer, R. Duran, M. Cuendet, O. Michielin (2022)
Safety and Efficacy of Ipilimumab plus Nivolumab and Sequential Selective Internal Radiation Therapy in Hepatic and Extrahepatic Metastatic Uveal MelanomaCancers, 14
E. Leede, M. Burgmans, C. Martini, F. Tijl, A. Erkel, J. Vuyk, E. Kapiteijn, C. Verhoef, C. Velde, A. Vahrmeijer (2016)
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver.Journal of visualized experiments : JoVE, 113
S. Kelderman, M. Kooij, A. Eertwegh, P. Soetekouw, R. Jansen, R. Brom, G. Hospers, J. Haanen, E. Kapiteijn, C. Blank (2013)
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)Acta Oncologica, 52
Arun Singh, M. Turell, A. Topham (2011)
Uveal melanoma: trends in incidence, treatment, and survival.Ophthalmology, 118 9
EM de Leede (2016)
e53795J Vis Exp, 113
(2020)
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRAUM)
Elina Rantala, M. Hernberg, T. Kivelä (2019)
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysisMelanoma Research, 29
Y. Najjar, K. Navrazhina, Fei Ding, Roma Bhatia, K. Tsai, Kelly Abbate, Barbara Durden, Z. Eroglu, S. Bhatia, Song Park, A. Chowdhary, S. Chandra, J. Kennedy, M. Ernstoff, P. Vachhani, J. Drabick, Arun Singh, Tan Xu, Jessica Yang, R. Carvajal, D. Manson, John Kirkwood, J. Cohen, R. Sullivan, Douglas Johnson, P. Funchain, A. Shoushtari (2020)
Ipilimumab plus nivolumab for patients with metastatic uveal melanoma: a multicenter, retrospective studyJournal for Immunotherapy of Cancer, 8
C. Lebbé, N. Meyer, L. Mortier, I. Márquez-Rodas, C. Robert, P. Rutkowski, A. Menzies, T. Eigentler, P. Ascierto, M. Smylie, D. Schadendorf, M. Ajaz, I. Svane, R. Gonzalez, L. Rollin, J. Lord-Bessen, A. Saci, E. Grigoryeva, J. Pigozzo (2019)
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma: Results From the Phase IIIb/IV CheckMate 511 TrialJournal of Clinical Oncology, 37
M. Hughes, J. Zager, M. Faries, H. Alexander, R. Royal, B. Wood, Junsung Choi, K. McCluskey, E. Whitman, S. Agarwala, G. Siskin, C. Nutting, M. Toomey, Carole Webb, T. Beresnev, J. Pingpank (2016)
Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver MetastasesAnnals of Surgical Oncology, 23
M. Burgmans, E. Leede, C. Martini, E. Kapiteijn, A. Vahrmeijer, A. Erkel (2015)
Percutaneous Isolated Hepatic Perfusion for the Treatment of Unresectable Liver MalignanciesCardiovascular and Interventional Radiology, 39
Riccardo Lencioni1, Josep 3 (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular CarcinomaSemin Liver Dis, 30
L. Khoja, L. Khoja, E. Atenafu, S. Suciu, S. Leyvraz, Takami Sato, E. Marshall, U. Keilholz, L. Zimmer, S. Patel, S. Piperno-Neumann, J. Piulats, T. Kivelä, C. Pfoehler, S. Bhatia, P. Huppert, L. Iersel, I. Vries, N. Penel, T. Vogl, T. Cheng, G. Fiorentini, F. Mouriaux, A. Tarhini, P. Patel, R. Carvajal, A. Joshua, A. Joshua (2019)
Meta-Analysis in Metastatic Uveal Melanoma to Determine Progression-Free and Overall Survival Benchmarks: an International Rare Cancers Initiative (IRCI) Ocular Melanoma study.Annals of oncology : official journal of the European Society for Medical Oncology
C. Drake (2015)
Combined Immune Checkpoint Blockade.Seminars in oncology, 42 4
P. Nathan, J. Hassel, P. Rutkowski, J. Baurain, M. Butler, M. Schlaak, R. Sullivan, S. Ochsenreither, R. Dummer, J. Kirkwood, A. Joshua, J. Sacco, A. Shoushtari, M. Orloff, J. Piulats, M. Milhem, A. Salama, B. Curti, L. Demidov, L. Gastaud, C. Mauch, Melinda Yushak, R. Carvajal, O. Hamid, S. Abdullah, C. Holland, H. Goodall, S. Piperno-Neumann (2021)
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma.The New England journal of medicine, 385 13
M. Diener-West, S. Reynolds, Donna Agugliaro, R. Caldwell, K. Cumming, J. Earle, B. Hawkins, J. Hayman, I. Jaiyesimi, L. Jampol, J. Kirkwood, W. Koh, D. Robertson, J. Shaw, B. Straatsma, J. Thoma (2005)
Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26.Archives of ophthalmology, 123 12
Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations
PurposeTo define a safe treatment dose of ipilimumab (IPI) and nivolumab (NIVO) when applied in combination with percutaneous hepatic perfusion with melphalan (M-PHP) in metastatic uveal melanoma (mUM) patients (NCT04283890), primary objective was defining a safe treatment dose of IPI/NIVO plus M-PHP. Toxicity was assessed according to Common Terminology Criteria for Adverse Events version 4.03 (CTCAEv4.03). Secondary objective was response rate, PFS and OS.Materials and MethodsPatients between 18–75 years with confirmed measurable hepatic mUM according to RECIST 1.1 and WHO performance score 0–1 were included. Intravenous IPI was applied at 1 mg/kg while NIVO dose was increased from 1 mg/kg in cohort 1 to 3 mg/kg in cohort 2. Transarterial melphalan dose for M-PHP was 3 mg/kg (maximum of 220 mg) in both cohorts. Treatment duration was 12 weeks, consisting of four 3-weekly courses IPI/NIVO and two 6-weekly M-PHPs.ResultsSeven patients were included with a median age of 63.6 years (range 50–74). Both dose levels were well tolerated without dose-limiting toxicities or deaths. Grade III/IV adverse events (AE) were observed in 2/3 patients in cohort 1 and in 3/4 patients in cohort 2, including Systemic Inflammatory Response Syndrome (SIRS), febrile neutropenia and cholecystitis. Grade I/II immune-related AEs occurred in all patients, including myositis, hypothyroidism, hepatitis and dermatitis. There were no dose-limiting toxicities. The safe IPI/NIVO dose was defined as IPI 1 mg/kg and NIVO 3 mg/kg. There was 1 complete response, 5 partial responses and 1 stable disease (3 ongoing responses with a median FU of 29.1 months).ConclusionCombining M-PHP with IPI/NIVO was safe in this small cohort of patients with mUM at a dose of IPI 1 mg/kg and NIVO 3 mg/kg.
CardioVascular and Interventional Radiology – Springer Journals
Published: Mar 1, 2023
Keywords: Advanced uveal melanoma; Liver metastases; Percutaneous hepatic perfusion; Melphalan; Immunotherapy
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.